<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9F250460-FEB3-4FCF-B06C-1340468D1058"><gtr:id>9F250460-FEB3-4FCF-B06C-1340468D1058</gtr:id><gtr:name>Viva Bioscience Limited</gtr:name><gtr:address><gtr:line1>1 COLLETON CRESCENT</gtr:line1><gtr:city>EXETER</gtr:city><gtr:postCode>EX2 4DG</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9F250460-FEB3-4FCF-B06C-1340468D1058" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>9F250460-FEB3-4FCF-B06C-1340468D1058</gtr:id><gtr:name>Viva Bioscience Limited</gtr:name><gtr:address><gtr:line1>1 COLLETON CRESCENT</gtr:line1><gtr:city>EXETER</gtr:city><gtr:postCode>EX2 4DG</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>22482.0</gtr:offerGrant><gtr:projectCost>29976.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C7F75A1E-ED0B-4518-AB49-7E1179023D7B"><gtr:id>C7F75A1E-ED0B-4518-AB49-7E1179023D7B</gtr:id><gtr:firstName>Tom</gtr:firstName><gtr:surname>Nicholson</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131689"><gtr:id>3D6408A7-ADC4-4DFF-860F-7DCE4043C121</gtr:id><gtr:title>Novel cell-based assays for drug screening and toxicity testing</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131689</gtr:grantReference><gtr:abstractText>Development of therapeutic drugs for Alzhemier?s, Parkinson?s and other neurodegenerative diseases is one of the key commitments agreed at the G8 Dementia Summit in December 2013 in London. VIVA proposes a feasibility study for the testing and validation of novel molecular tools and cell-based assays for use in the discovery and development of drugs for the treatment of such conditions.</gtr:abstractText><gtr:fund><gtr:end>2014-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>22482</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131689</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>